With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...

INDICATION: Sleep apnea In vitro , rat and pig studies identified a phenoxyaminoindane-based SLC9A3 inhibitor that could help treat sleep apnea. Screening of a small molecule library in a cell-based assay, followed by chemical synthesis and...

An underpowered cohort appears to be the culprit behind the Phase III miss for betrixaban, but Portola Pharmaceuticals Inc. plans to pursue an NDA submission for the oral Factor Xa inhibitor based on the totality...

Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx agreed to terminate a 2009 deal under which Sanofi gained exclusive, worldwide rights to SAR279356 , which is being developed to treat serious...

The U.S. Court of Appeals for the Federal Circuit ruled that a patent covering cDNA should be awarded to the party "who first had in hand the actual isolated DNA," regardless of whether the party...

The partners extended by three years a 2010 research collaboration to develop treatments for unmet medical needs, including rare diseases. The partners said special emphasis will be placed on translational research projects. Projects under discussion...

Sanofi said that its Sanofi-Aventis R&D France project, which employs more than 5,000 positions, could lead to a net reduction of 207 positions. The pharma also confirmed that it will refocus R&D in the sites...

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibroblast growth factor receptor (FGFR) Two separate studies identified an allosteric inhibitor of FGFR that could help treat cancer. In...

Sanofi and collaborators at the Flanders Institute for Biotechnology at Catholic University Leuven have serendipitously discovered an allosteric inhibitor of the cancer target fibroblast growth factor receptor . The team hopes the allosteric mechanism will lead...

Sanofi's Sanofi U.S. Services Inc. and sanofi-aventis U.S. LLC companies will pay $109 million to the U.S. Attorney's Office, District of Massachusetts, the U.S. Department of Justice and multiple states to resolve a 2010 False...